Singletto
Singletto is a Seattle-based startup that markets virus-killing medical masks using Oxafence technology, and has received FDA approval...
Facts
- HQ
- Seattle, Washington, United States
- Sectors
- Medical devices, Healthtech, Personal protective equipment, Manufacturing
- Founded
- 2020 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Singletto Inc Seattle business license
- Stage
- startup
- Total raised
- $11M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $100K · Mar 2026 SEC Form D
- Founders
- James (Jim) Chen, MD, Thomas (Tom) Lendvay, MD
Recent coverage
Front-page news, podcasts and videos about Singletto
Seattle Startup Singletto Launches FDA-Approved Virus-Killing Masks on Amazon Following $10M Funding and DARPA Support
Seattle startup Singletto, with $10 million in funding and support from DARPA, has launched FDA-approved virus-neutralizing face masks on Amazon using its Oxafence Active Protection technology that kills 99.9% of certain viruses. The masks are the only FDA-cleared products in the U.S. that inactivate tested viruses and may have applications in healthcare and national security.
Seattle Startup Singletto Gains FDA Approval for Virus-Killing Oxafence Surgical Masks
Seattle startup Singletto received FDA approval for its Oxafence technology, a methylene blue-treated surgical mask that kills 99.9% of certain viruses within five minutes. The masks are already in use in New Zealand and represent a significant advancement over traditional masks by actively inactivating pathogens.
People
-
Thomas Lendvay Executive, Chief Medical Officer, Executive Officer, Director
-
John Bjornson Executive Officer, Director, Co-Founder and CEO
